Blurbs

Analysts Are Bullish on Top Healthcare Stocks: Avanos Medical (AVNS), Karuna Therapeutics (KRTX)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Avanos Medical (AVNSResearch Report), Karuna Therapeutics (KRTXResearch Report) and Beam Therapeutics (BEAMResearch Report) with bullish sentiments.

Avanos Medical (AVNS)

In a report released today, Matthew Mishan from KeyBanc maintained a Buy rating on Avanos Medical, with a price target of $38.00. The company’s shares closed last Tuesday at $28.84.

According to TipRanks.com, Mishan is a 4-star analyst with an average return of 7.1% and a 57.4% success rate. Mishan covers the Healthcare sector, focusing on stocks such as Baxter International, PROCEPT BioRobotics, and ICU Medical.

Currently, the analyst consensus on Avanos Medical is a Hold with an average price target of $31.33.

See the top stocks recommended by analysts >>

Karuna Therapeutics (KRTX)

In a report released today, Jacob Hughes from Wells Fargo maintained a Buy rating on Karuna Therapeutics, with a price target of $264.00. The company’s shares closed last Tuesday at $228.45.

Hughes has an average return of 16.1% when recommending Karuna Therapeutics.

According to TipRanks.com, Hughes is ranked #4239 out of 7991 analysts.

Currently, the analyst consensus on Karuna Therapeutics is a Strong Buy with an average price target of $241.07, implying a -1.9% downside from current levels. In a report issued on August 8, Citigroup also maintained a Buy rating on the stock with a $280.00 price target.

Beam Therapeutics (BEAM)

In a report released today, Rick Bienkowski from SVB Securities maintained a Buy rating on Beam Therapeutics, with a price target of $113.00. The company’s shares closed last Tuesday at $60.96.

According to TipRanks.com, Bienkowski is ranked #5529 out of 7991 analysts.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Beam Therapeutics with a $90.25 average price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on AVNS:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More